The Open University
The Mechanistic Role of Long Non-coding RNAs in Advanced Prostate Cancer Response to Therapy
Abstract
dc:description.abstractProstate cancer is one of the most common malignancies and the fifth leading cause of cancer related deaths in males, worldwide. It is commonly treated using androgen deprivation therapy (ADT), but around 25% develop ADT resistance and are called Castration-Resistant Prostate Cancers (CRPCs). Therapies currently used for CRPC treatment include: the new generation anti-androgen enzalutamide, the taxane cabazitaxel and carboplatin. Despite the prolonged survival resulting from these treatments, CRPC is still incurable. Recent evidence suggests that long non-coding RNAs (lncRNAs) promote drug resistance. The lncRNA <i>HORAS5</i> (i.e.<i> linc00161</i>) regulates drug response in different cancers and is upregulated in CRPC versus hormone-sensitive patient-derived xenografts (PDXs), thereby stimulating pro-survival mechanisms. This project has investigated whether <i>HORAS5</i> has a role in CRPC response to therapy. CRPC cells have been treated with different concentrations of cabazitaxel, carboplatin and enzalutamide. Cabazitaxel exposure increases <i>HORAS5</i> expression, in androgen receptor-positive (AR+) and -negative (AR–) prostate cancer cells and <i>HORAS5</i> overexpression decreases cabazitaxel sensitivity and cell apoptosis. <i>HORAS5</i> RNA interference (RNAi) increases cabazitaxel sensitivity and cell apoptosis. Next-generation RNA sequencing and real time qPCR have shown that the anti-apoptotic factor <i>BCL2A1</i> is significantly upregulated upon <i>HORAS5</i> overexpression in AR- prostate cancer cells exposed to cabazitaxel. <i>BCL2A1</i> silencing decreases cell count and increases apoptosis of prostate cancer cells exposed to cabazitaxel. <i>HORAS5</i> and <i>BCL2A1</i> upregulation is associated with decreased survival in prostate cancer patients and <i>HORAS5</i> is upregulated in clinical samples from prostate cancer patients exposed to taxanes. Transfection of CRPC cells with <i>HORAS5</i>-targeting antisense oligonucleotides (ASOs) efficiently reduces <i>HORAS5</i> expression, thereby decreasing cabazitaxel IC<sub>50</sub> when tested in combination with this drug. Overall, this project shows that <i>HORAS5</i> stimulates <i>BCL2A1</i> expression in prostate cancer cells, thereby reducing caspase-mediated apoptosis. This leads to increased cabazitaxel resistance. The clinical relevance of <i>HORAS5</i> expression and the effect of <i>HORAS5</i>-targeting ASOs shown in this thesis highlight the translational potential of <i>HORAS5</i> modulation. This work sheds light on the relevance of lncRNAs in cancer drug resistance and proposes the use of <i>HORAS5</i> as a future therapeutic target to increase therapy efficacy in CRPC.
Degree
thesis:*- Name dc:type.qualificationname
- phd
- Level dc:type.qualificationlevel
- doctoral
- Grantor dc:publisher.institution
- The Open University
- Year dc:date.issued
- 2020
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Pucci, Perla
Rights
- Language dc:language
- en